Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus vaccine + zoster vaccine recombinant, adjuvanted
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Abrysvo + Shingrix refers to the coadministration of two distinct vaccines: Pfizer's Abrysvo (RSVpreF) and GSK's Shingrix (HZ/su). Abrysvo is a bivalent recombinant protein subunit vaccine designed to prevent respiratory syncytial virus (RSV) infection by targeting the prefusion F protein of both RSV A and B subgroups. Shingrix is a recombinant zoster vaccine containing the varicella-zoster virus (VZV) glycoprotein E (gE) antigen combined with the AS01B adjuvant system, used to prevent herpes zoster (shingles) and postherpetic neuralgia. The simultaneous administration of these vaccines is being evaluated in Phase 3 clinical trials (e.g., NCT05842967) to assess safety, tolerability, and immunogenicity in adults aged 50 and older, aiming to improve vaccination compliance by reducing the number of healthcare visits required for immunization.
- Other names
- RSVpreF + HZ/suRSVpreF vaccine + HZ/su vaccineAbrysvo + Shingrix
02
Targets
RSV F (Respiratory syncytial virus fusion protein)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on respiratory syncytial virus vaccine + zoster vaccine recombinant, adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus vaccine + zoster vaccine recombinant, adjuvanted.